Cargando…

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series

BACKGROUND: Buprenorphine, a partial opioid agonist, displaces full opioid agonists from receptors and may impede surgical pain management. We report the effects of a sublingual formulation of buprenorphine-naloxone, Suboxone (SL-BUP), on perioperative pain management. METHODS: We identified all adu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Yvette N., Deljou, Atousa, Weingarten, Toby N., Schroeder, Darrell R., Sprung, Juraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507026/ https://www.ncbi.nlm.nih.gov/pubmed/31068127 http://dx.doi.org/10.1186/s12871-019-0745-3

Ejemplares similares

Effects of Sugammadex on Time of First Postoperative Bowel Movement: A Retrospective Analysis
por: Deljou, Atousa, et al.
Publicado: (2019)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
por: Soyka, Michael
Publicado: (2015)

Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series
por: Deljou, Atousa, et al.
Publicado: (2018)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
por: Kaski, Shane, et al.
Publicado: (2021)

Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film
por: Gunderson, Erik W., et al.
Publicado: (2016)

Population pharmacokinetics of buprenorphine and naloxone sublingual combination in Chinese healthy volunteers and patients with opioid use disorder: Model-based dose optimization
por: Gu, Meng, et al.
Publicado: (2023)

Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteers
por: Fischer, Andreas, et al.
Publicado: (2015)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study
por: Hoffman, Kent, et al.
Publicado: (2017)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy
por: Feng, Hwa‐Ping, et al.
Publicado: (2018)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: A case report
por: Behan, Jennifer, et al.
Publicado: (2016)

Perioperative Pain Management for Median Sternotomy in a Patient on Chronic Buprenorphine/Naloxone Maintenance Therapy: Avoiding Opioids in Patients at Risk for Relapse
por: Alalade, Emmanuel, et al.
Publicado: (2020)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence During Pregnancy: Maternal and Neonatal Outcomes”
por: Newman, Robert G., et al.
Publicado: (2013)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

Six-month buprenorphine-naloxone treatment is associated with neurocognitive function improvement in opioid dependence
por: Ghosh, Abhishek, et al.
Publicado: (2022)

Effects of changes in intraoperative management on recovery from anesthesia: a review of practice improvement initiative
por: Weingarten, Toby N, et al.
Publicado: (2015)

Post-operative Analgesia in Opioid Dependent Patients: Comparison of Intravenous Morphine and Sublingual Buprenorphine
por: Alizadeh, Shaabanali, et al.
Publicado: (2015)

Relapse rates among veterans on maintenance doses of combination buprenorphine and naloxone for opioid use disorder
por: Binger, Katie J., et al.
Publicado: (2020)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Postoperative respiratory depression after hysterectomy
por: Laporta, Mariana L., et al.
Publicado: (2021)

Evaluation of the Effectiveness of Buprenorphine-Naloxone on Opioid Overdose and Death among Insured Patients with Opioid Use Disorder in the United States
por: Sun, Tianyu, et al.
Publicado: (2022)

Opioid Drug Utilization and Cost Outcomes Associated With the Use of Buprenorphine-Naloxone in Patients With a History of Prescription Opioid Use
por: Kaur, Aman Deep, et al.
Publicado: (2008)

Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine/Naloxone Films: A Case Series
por: Cedeño, Erica, et al.
Publicado: (2022)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Patients with glycogen storage diseases undergoing anesthesia: a case series
por: Gurrieri, Carmelina, et al.
Publicado: (2017)

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy
por: Mattoo, Surendra K., et al.
Publicado: (2020)

Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion
por: Saloner, Brendan, et al.
Publicado: (2018)

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
por: Bestepe, Engin Emrem, et al.
Publicado: (2020)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

Evaluation of buprenorphine/naloxone dose and use of sedating supportive medication on treatment outcomes in veterans with opioid use disorder
por: Kapuganti, Amber, et al.
Publicado: (2018)

Buprenorphine/naloxone access for people with opioid use disorder in correctional facilities: taking steps to support knowledge translation
por: Regenstreif, Lori, et al.
Publicado: (2022)

Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone
por: Kline, Anna, et al.
Publicado: (2023)

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder
por: Wipper, Benjamin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17v32jsnrfjr87m875ogpgp2vi